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index dose of 90mg. CONCLUSIONS: The real-world distribution of ustekinumab is
consistent with dosing recommendations in the prescribing information.
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INTRAVITREAL INJECTIONS IN AUSTRIA - RESULTS OF AN EXPERT SURVEY
AND COMPARISON WITH UTILISATION RATES FROM THE AUSTRIAN MINISTRY
OF HEALTH
Vavrovsky AD1, Kieselbach G2
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OBJECTIVES: Intravitreal injections are an important treatment options for pa-
tients with various ophthalmologic diseases in Austria. There is a lack of data on
the real-life use of intravitreal injections in Austria. METHODS: A standardized
questionnaire on practice patternswas developed in cooperationwith theAustrian
Society of ophthalmologic surgeons. The survey was distributed among treating
ophthalmologists and results were compared to data from the Austrianministry of
health an prevalence-adjusted results from a landmark study in intravitreal
injections.RESULTS:The response rate to the surveywas 100%. Twenty-six centers
across Austria participated and reported a cumulative number of 30,124 patients
treated with intravitreal injections in 2010. The Austrianministry of health reports
30,733 intravitreal injections in 2010. Despite the fact that we have covered more
than 98% of cases in our survey, the disparities across different Austrian counties
became apparent, from the province Burgenland with only 17% of patients receiv-
ing intravitreal injections to the province of Vienna, where 44% of patients received
adequate treatment as per the CATT study. Based on a prevalence rate of 0.162%,
13,550 cases of wet AMD are expected in Austria. As there is currently no other
treatment option forwet AMD than intravitreal injections and a recent study found
the optimal dosing frequency to be seven injections per year, the number of intra-
vitreal injections should be much higher - 94,800 injections are expected if every
patient is treated according to the finding from theCATT study, namely 7 injections
per affected eye per year. As both eyes are affected in most patients, the number
should be even higher. CONCLUSIONS:More research is needed to increase infor-
mation and transparency around the epidemiology of diseases treated by intravit-
real injection and the real-life injection rates in Austria.
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OBJECTIVES: To assess real-world characteristics and severity of United States
health plan members with psoriasis receiving ustekinumab. METHODS: Medical/
pharmacy claims from the HealthCore Integrated Research Database (HIRDSM)
were analyzed. Patients included had/were:  1 ustekinumab medical/ pharmacy
claim (09/01/2009-11/30/2010); aged 18 years old at time of first ustekinumab
claim (index date); 1 psoriasis diagnosis code; and  12 months continuous en-
rollment pre-index. Patients with a medical/ pharmacy claim for another biologic
at index were excluded. Patient characteristics and severity were evaluated for the
12months pre-index, and included comorbidities, history of biologic use/psoriasis-
related topical steroids/ non-biologic systemic medications, and psoriasis-related
healthcare utilization. RESULTS: 374 patients were included (meanSD age was
4812 years; 56.4% were male). MeanSD Deyo-Charlson Comorbidity Index was
0.550.97. Dyslipidemia (46.3%) and hypertension (43.3%) were the twomost prev-
alent comorbidities prior to initiating ustekinumab. Themajority (69.5%; n260) of
patients had a history of biologic experience. Of those with pre-index biologic use,
22.3% had experience with2 biologics prior to ustekinumab. Themajority (58.0%)
of all patients had history with pre-index topical steroids; 36.4% of all patients had
history with non-biologic, systemic medications. Patients had a meanSD of
4.03.0 psoriasis-related office visits pre-index. Few had a psoriasis-related hospi-
talization (2.7%) or emergency room (ER) visit (1.9%)with ameanSDof 1.10.3 and
1.41.1 admissions or visits among patients with hospitalization or ER visit,
respectively. CONCLUSIONS: The majority of psoriasis patients receiving usteki-
numab were biologic-experienced, and nearly half had pre-existing dyslipidemia
and/or hypertension. Non-biologic, systemic medication use was evident in over a
third of all patients prior to ustekinumab. These data may be incorporated in pso-
riasis health plan programs, as there may be an opportunity to consider dyslipide-
mia and hypertension management. Furthermore, these data may be compared
with existing severity data for other psoriasis biologics.
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OBJECTIVES:Ustekinumab, a biologic used inmoderate-to-severe plaque psoriasis
(PsO), is dosed at 45mg or 90mg with health care provider (HCP) administration at
weeks 0, 4, and every 12 weeks thereafter. The objective of this study was to eval-
uate the observed dosing patterns and HCP office visits for psoriasis patients re-
ceiving ustekinumab. METHODS: The IMS LifeLink™ database was utilized to an-
alyze patients with an index pharmacy claim of ustekinumab therapy initiated
September 25, 2009 toMarch 31, 2011. Inclusion criteria: patients aged 18 years at
index,  1 PsO diagnosis code before or on index, and  360 days pre-index con-
tinuous enrollment. Ustekinumab dosing patterns included the proportion of 45mg
and 90mg doses at each of the first four fills and the time between injections.
Increases or decreases in dose between subsequent fills were assessed. Office visits
were evaluated for the 180-day post-index time period (patients required  180
days post-index continuous enrollment). RESULTS: A total of 306 PsO patients
receiving ustekinumab were evaluated. The proportion of index 45mg/90mg use
was 65%/35%. The proportion of 45mg use spanned 59%-61% across remaining fills.
Median (mean SD) interval timeswere 28 (3020), 84 (8732), and 85 (9033) days
for first to second, second to third, and third to fourth doses, respectively. Changes
in dose were observed for  7% of patients at each fill. Patients (n280) incurred a
median (mean) number of 4 (5.5) all-cause and 3 (2.5) PsO-related HCP office visits
during the first six-months after initiating therapy. CONCLUSIONS: These results
suggest that most PsO patients are initiated with a 45 mg dose. Nearly 93% of all
patients at each fill did not require dose changes over the first 4 prescriptions. The
observed interval patterns were consistent with the recommended ustekinumab
administration schedule. Additionally, patients experienced PsO-related HCP in-
teractions commensurate with the number of ustekinumab doses expected.
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BACKGROUND: Plaque psoriasis is a chronic disease characterized by scaly plaques
that can itch and bleed. When psoriasis covers over 10% of the body it is classified
as moderate to severe, and can have a major impact on patient quality of life.
OBJECTIVES: The primary objective was to determine the relationship between
plaque psoriasis severity and health outcomes, work productivity, and activity
impairment among patients with moderate to severe psoriasis. METHODS: The
sample included 199 patients: 179 respondents had plaque psoriasis, 20 had plaque
and inverse psoriasis. Three psoriasis symptoms were studied (itching, pain, and
scaling). A structural equations frameworkwas used to estimate the effect of these
symptoms on patient outcomes. In the first stage, each severity variable was re-
gressed on a set of covariates to generate a predicted severity score. These pre-
dicted values were then placed in a second stage model with patient mental and
physical scores (SF-12), work productivity, and activity impairment indicators as
the dependent variables. RESULTS: Severity of itching had a negative effect on
patients’ SF-12 physical and mental component scores. The effects were margin-
ally significant (p0.06). Severity of pain was significant for physical and mental
health (p0.02). Patients were more likely to miss work because of greater itching
(OR: 2.31, CI [1.30, 4.10]), pain (OR: 1.78, CI [1.25, 2.52]), and scaling (OR: 2.15, CI [1.31,
3.52]) symptoms. These symptoms also affected productivity. More severe itching
(OR: 1.74, CI [1.03, 2.95]), scaling (OR: 1.84, CI [1.16, 2.90]), and pain symptoms (OR:
1.53, CI [1.12, 2.09]) increased the likelihood that a patient would be less productive
on the job. CONCLUSIONS: Plaque psoriasis has a significant effect on patients’
quality of life. In addition to greater mental and physical pain, patients are more
likely to miss work and have diminished productivity as the severity of symptoms
increases.
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Bacterial eye inflammation (primarily conjunctivitis) is one of the most common
cause of temporary disability in ophthalmology. Furthermore, bacterial eye inflam-
mation is one of themost common complications in the practice of ophthalmologic
surgeries and it impacts the primary operation outcome. Thus, optimization of
drug therapy and prophylaxis of bacterial eye inflammation is an actual problem of
health care system in Russia. OBJECTIVES: We provided two pharmacoeconomic
studies. In the first one a treatment of bacterial conjunctivitis with fluoroquinolo-
nes (Vigamox (moxifloxacin), Ophtakvix and Signicef (levofloxacin), Cipromed (cip-
rofloxacin) and Floxal (ofloxacin) eye-drops was considered and the second study
provided pharmacoeconomic evaluation of prophylaxis of postoperative bacterial
eye inflammation with combined eye-drops drugs of antibiotic and glucocortico-
steroid (Tobradex (tobramicinedexamethasone) andCombinil-Duo (ciprofloxacin
dexamethasone)). METHODS: Cost-efficacy analysis and cost-of-illness analysis
were used. Direct and indirect costs were considered for bacterial conjunctivitis
study and direct only costs were considered for postoperative bacterial eye inflam-
mation in pharmacoeconomic study. RESULTS: The first study has found that
Vigamox is a dominant drug to the other ones. The cost-efficacy ratio (CER) (cost of
1% of patients with successful treatment) for Vigamox it was – 1415 RUB, for Oph-
takvix – 1652 RUB, for Signicef – 1458 RUB, for Cipromed – 1674 RUB, for Floxal – 1630
RUB. Cost-efficacy analysis of postoperative bacterial eye inflammation prophy-
laxis has shown that Tobradex has dominant technology compared with to Com-
binil-Duo. CER (cost of 1% of patientswithout sign of inflammation to 14th day after
operation) for Tobradex it was – 453 RUB, for Combinil-Duo – 515 RUB.
CONCLUSIONS: Two conducted pharmacoeconomic studies show benefit of Viga-
A255V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
mox and Tobradex to the other ones from the cost-efficacy perspective in treat-
ment of bacterial conjunctivitis and the postoperative of bacterial eye inflamma-
tion prophylaxis respectively in Russia Federation.
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COMPARISON OF THE SKINDEX-17 QUALITY OF LIFE QUESTIONNAIRE WITH
THE SKINDEX-29 IN A LARGE SAMPLE OF DERMATOLOGICAL OUTPATIENTS
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OBJECTIVES: The utilization of health-related quality of life (HRQoL) question-
naires in the routine clinical practice is hampered by several factors, including
their length and thus the time needed to complete and score them. For this reason,
growing efforts are devoted both to create short questionnaires and to shorten
existing ones. The Skindex-17 is a dermatological HRQoL instrument that was
derived from the Skindex-29 using Rasch analysis. It is constituted by 17 items
instead of 29 and answers are given on a three-point scale instead of five. The aim
of this study was to compare information obtained by the Skindex-29 and the
Skindex-17 in a large sample of dermatological outpatients. METHODS: We com-
pared the Skindex-29 with the Skindex-17 scores in 2487 patients with several
dermatological conditions, using the intraclass correlation coefficients.To verify
that responses to individual items were affected by diagnosis in a comparable way
in the two instrumentswe performed aDifferential Item Functioning (DIF) analysis
on random subsamples (n230) of our study population RESULTS: The overall
correlation was 0.957 for the symptoms scale and 0.940 for the psychosocial scale.
The values were very similar for all the diseases. The concordance between the
levels of severity of the Skindex subscales in the two instruments was also very
high. Although several items of the Skindex-17 showed a significant DIF, it is to
note that in all cases the corresponding Skindex-29 items also had a significant DIF.
CONCLUSIONS: In conclusion, the Skindex-17 provided very similar information
compared to the Skindex-29, with the advantage of being shorter and to fit some
important psychometric properties.
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